Pasithea Therapeutics -CW26KTTAWPreferred / convertible
13F holders, Q1 2024 (March 31)6holders
1famous investor
$0.01avg. 13F price*
At the end of Q1 2024, 6 institutions reported holding Pasithea Therapeutics -CW26 (KTTAW) in their 13F filings. The largest holders were Kepos Capital LP ($4K), Warberg Asset Management LLC ($4K) and Armistice Capital, LLC ($615). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Pasithea Therapeutics -CW26
- CUSIP
- 70261F111
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
Ownership 6 holders
| Kepos Capital LP | — | No change | 334,600 | $4K |
| Warberg Asset Management LLC | — | No change | 289,868 | $4K |
| Armistice Capital, LLC | — | Reduce -95.0% | 50,000 | $615 |
| Marex Group Ltd | — | No change | 25,000 | $308 |
| Citadel Advisors | — | Add +0.8% | 13,204 | $162 |
| UBS Group AG | — | New | 34 | $0 |
"% of holder's portfolio" is KTTAW's weight in each manager's 13F, not the share of Pasithea Therapeutics -CW26 the manager owns.